JAK3 and renal cell carcinoma: Several studies described defects in different components of the IL-2R signaling pathway, resulting in decreased T cell proliferation, such as the absence of CD25 expression [29], impaired STAT1 and STAT5 activation [30] or soluble products released from renal cell carcinoma that suppress JAK3 [24].